Adventrx joins VA in drug studies

[Guest guest]

Adventrx joins VA in drug studies

UNION-TRIBUNE

May 26, 2007

Adventrx Pharmaceuticals, which is developing therapies for cancer

and infectious disease, said it has finalized a research and

development agreement that allows the Department of Veterans Affairs

clinical sites to participate in the company's Phase 3 clinical trial

of ANX-510 for the treatment of metastatic colorectal cancer.

The San Diego-based company said it has clinical trial agreements

with three regional VA centers.

By working with the VA centers, the company said it expects to speed

enrollment in its clinical trials. More than 1,200 patients will be

enrolled in the trials to study the effects of ANX-510 in combination

with chemotherapy agents.

Amylin buys stake in biotech firm

Diabetes drug-maker Amylin Pharmaceuticals has invested $10 million

in BioSeek, a Bay Area company with which it is collaborating to look

for possible new drug compounds.

San Diego-based Amylin brings its library of proprietary polypeptide

hormones to the partnership. And BioSeek brings its BioMAP screening

system.

The BioMAP is a human cell-based screening system. The cells can be

exposed to different compounds, so that the changes created in the

protein levels within the cells can help determine which biological

pathways are being affected.

http://www.signonsandiego.com/news/business/20070526-9999-

1b26bizbrfs.html